Drug Trial Radar · NCT03319732
A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS
Last checked: Nov 19, 2026Latest source record: Aug 9, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
323
Actual
Start
Apr 3, 2018
Primary completion
Jan 27, 2020
Study completion Jun 11, 2020
Sponsor
- Lead sponsor
- RVL Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Osmotica Pharmaceutical US LLC
- First posted
- Oct 24, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Spasticity is a common complication in MS and occurs in up to 84% of patients. The main sign of spasticity is resistance to passive limb movement characterized by increased resistance to stretching, clonus, and exaggerated deep reflexes. Osmotica Pharmaceutical is currently developing arbaclofen extended-release tablets (AERT) for the treatment of spasticity in patients with MS.
Conditions
- Multiple Sclerosis
- Spasticity, Muscle
Interventions
ArbaclofenDrug
Arbaclofen is the active R enantiomer of baclofen.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events, Change in Vital Signs, Clinical Laboratory Test Results, 12-lead ECGs, USP Questionnaire, and C-SSRS ResultsTime frame: over 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Neuro Pain Medical Center
Fresno, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.